Kura Oncology
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Kura Oncology and other ETFs, options, and stocks.About KURA
Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias.
CEOTroy E. Wilson
CEOTroy E. Wilson
Employees192
Employees192
HeadquartersSan Diego, California
HeadquartersSan Diego, California
Founded2014
Founded2014
Employees192
Employees192
KURA Key Statistics
Market cap513.82M
Market cap513.82M
Price-Earnings ratio-2.70
Price-Earnings ratio-2.70
Dividend yield—
Dividend yield—
Average volume1.18M
Average volume1.18M
High today$6.07
High today$6.07
Low today$5.48
Low today$5.48
Open price$5.65
Open price$5.65
Volume506.55K
Volume506.55K
52 Week high$23.48
52 Week high$23.48
52 Week low$5.41
52 Week low$5.41
KURA News
Simply Wall St 1d
Analysts Just Shipped A Captivating Upgrade To Their Kura Oncology, Inc. EstimatesKura Oncology, Inc. ( ) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's forecasts. The consensus st...
Analyst ratings
87%
of 15 ratingsBuy
86.7%
Hold
13.3%
Sell
0%
People also own
Based on the portfolios of people who own KURA. This list is generated using Robinhood data, and it’s not a recommendation.